Viking Therapeutics
(NASDAQ) VKTX
Viking Therapeutics Financials at a Glance
Market Cap
$3.76B
Revenue (TTM)
$0.00
Net Income (TTM)
$359.64M
EPS (TTM)
$-3.18
P/E Ratio
-10.22
Dividend
$0.00
Beta (Volatility)
1.24 (Average)
Dividend
$0.00
Beta (Volatility)
1.24 (Average)
Price
$30.80
Volume
31,613
Open
$32.52
Price
$30.80
Volume
31,613
Open
$32.52
Previous Close
$32.52
Daily Range
$30.70 - $32.52
52-Week Range
$18.92 - $43.15
Dividend
$0.00
Beta (Volatility)
1.24 (Average)
Price
$30.80
Volume
31,613
Open
$32.52
Previous Close
$32.52
Daily Range
$30.70 - $32.52
52-Week Range
$18.92 - $43.15
VKTX News
VKTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Viking Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
53
CEO
Brian Lian, PhD, MBA
Website
www.vikingtherapeutics.comHeadquarters
San Diego, CA 92121, US
VKTX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-47%
Return on Capital
-62%
Return on Assets
-50%
Earnings Yield
-9.78%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$3.76B
Shares Outstanding
115.55M
Volume
31.61K
Short Interest
0.00%
Avg. Volume
2.98M
Financials (TTM)
Gross Profit
$431.00K
Operating Income
$393.34M
EBITDA
$393.34M
Operating Cash Flow
$278.69M
Capital Expenditure
$0.00
Free Cash Flow
$278.69M
Cash & ST Invst.
$705.74M
Total Debt
$137.00K
Viking Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$94.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$3.76B
N/A
Market Cap/Employee
$83.51M
N/A
Employees
45
N/A
Net Income
$157.66M
-345.2%
EBITDA
$164.74M
-257.1%
Quarterly Fundamentals
Net Cash
$705.60M
-21.7%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$137.00K
-72.0%
Return on Assets
-50.25%
N/A
Return on Invested Capital
-61.55%
N/A
Free Cash Flow
$85.29M
-173.5%
Operating Cash Flow
$85.29M
-173.5%